Description: IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Home Page: in8bio.com
INAB Technical Analysis
350 5th Avenue
New York,
NY
10118
United States
Phone:
646 600 6438
Officers
| Name | Title |
|---|---|
| Mr. Tai-Wei Ho | Co-Founder, Pres, CEO & Director |
| Dr. Lawrence S. Lamb Ph.D. | Exec. VP, Co-Founder & Chief Scientific Officer |
| Mr. Patrick McCall CPA | CFO & Sec. |
| Dr. Kate Rochlin Ph.D. | Chief Operating Officer |
| Dr. Trishna Goswami M.D. | Chief Medical Officer |
| Dr. Kenneth R. LaMontagne Ph.D. | Sr. VP of Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9559 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-07-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |